Venous to Arterial Carbon Dioxide Difference (P₍ᵥ-ₐ₎CO₂): Predictor of Septic Patient Prognosis Depending on the ScvO₂
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Sep 22, 2017
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with a diagnosis of septic shock
- • Initial lactate in patients should be≥ 2 mmol / L.
- • The presence of circulatory insufficiency defined by a systolic blood pressure ≤ 90 mmHg (or a drop in blood pressure≥ 50 mmHg in hypertensive patients)
- • One or more of the following: oliguria defined as diuresis≤ 0,5 mL/ kg / h for at least two hours; the presence of signs of cerebral hypoperfusion; the highlighting of mottling
- • The presence of a femoral arterial catheter and a central venous line in the superior vena cava position
- • Hemodynamic monitoring with semi-invasive monitoring of cardiac output with thermodilution
- Exclusion Criteria:
- • Patient no longer in the initial phase of septic shock
- • Absence of semi-invasive cardiac monitoring with thermodilution
- • Vulnerable people
- • Absence of informed consent
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Patients applied
Trial Officials
jean olivier ARNAUD
Study Director
Assistance Publique Hopitaux De Marseille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials